Literature DB >> 19747357

Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden.

Melissa S Y Thong1, Floortje Mols, Paul J M Kil, Ida J Korfage, Lonneke V van de Poll-Franse.   

Abstract

OBJECTIVE: To assess and identify factors associated with the long-term health-related quality of life (HRQL) of prostate cancer survivors managed expectantly, as patients with low-risk prostate cancer can be managed with active surveillance (AS), but research on associated long-term HRQL is scarce. PATIENTS AND METHODS: From the population-based Eindhoven Cancer Registry, 71 men managed with AS were matched with 71 survivors who had similar demographic and clinical characteristics but treated with external beam radiotherapy (RT). All were diagnosed between 1994 and 1998. HRQL data were collected 5-10 years after diagnosis. Patients completed generic- (Short Form-36) and cancer-specific (Quality of Life - Cancer Survivors) HRQL instruments, and symptom burden (Expanded Prostate Cancer Index, Sexual Activity) questionnaires.
RESULTS: Patients on AS were comparable to those treated with RT for most generic- and disease-specific HRQL dimensions. Patients treated with RT had poorer mean (sd) bowel function scores, of 87.1 (13.1) vs 92.8 (10.7) (P < 0.001), more bother with bowel function, at 85.0 (16.4) vs 93.7 (10.1) (P < 0.001), and more problems with getting an erection (68% vs 47%, P = 0.005). Multivariate regression analyses (corrected for comorbidity and clinical disease progression) indicated that the management strategy independently predicted differences in physical functioning, bodily pain, spiritual and total well-being, and bowel function and bowel bother.
CONCLUSIONS: Patients managed expectantly at initial diagnosis (AS) have comparable HRQL and a lower symptom burden than patients treated with RT up to 10 years after the diagnosis.

Entities:  

Mesh:

Year:  2009        PMID: 19747357     DOI: 10.1111/j.1464-410X.2009.08815.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

1.  Toward ethically responsible choice architecture in prostate cancer treatment decision-making.

Authors:  J S Blumenthal-Barby; Denise Lee; Robert J Volk
Journal:  CA Cancer J Clin       Date:  2015-05-21       Impact factor: 508.702

2.  Quality of life among men with low-risk prostate cancer during the first year following diagnosis: the PREPARE prospective cohort study.

Authors:  Kathryn L Taylor; George Luta; Richard M Hoffman; Kimberly M Davis; Tania Lobo; Yingjun Zhou; Amethyst Leimpeter; Jun Shan; Roxanne E Jensen; David S Aaronson; Stephen K Van Den Eeden
Journal:  Transl Behav Med       Date:  2018-03-01       Impact factor: 3.046

3.  Quality-of-life effects of prostate-specific antigen screening.

Authors:  Eveline A M Heijnsdijk; Elisabeth M Wever; Anssi Auvinen; Jonas Hugosson; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Arnauld Villers; Alvaro Páez; Sue M Moss; Marco Zappa; Teuvo L J Tammela; Tuukka Mäkinen; Sigrid Carlsson; Ida J Korfage; Marie-Louise Essink-Bot; Suzie J Otto; Gerrit Draisma; Chris H Bangma; Monique J Roobol; Fritz H Schröder; Harry J de Koning
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

4.  Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls-results from a population-based study.

Authors:  Salome Adam; Daniela Doege; Lena Koch-Gallenkamp; Melissa S Y Thong; Heike Bertram; Andrea Eberle; Bernd Holleczek; Ron Pritzkuleit; Mechthild Waldeyer-Sauerland; Annika Waldmann; Sylke Ruth Zeissig; Lina Jansen; Sabine Rohrmann; Hermann Brenner; Volker Arndt
Journal:  Support Care Cancer       Date:  2019-11-18       Impact factor: 3.603

5.  Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance.

Authors:  Patricia A Parker; John W Davis; David M Latini; George Baum; Xuemei Wang; John F Ward; Deborah Kuban; Steven J Frank; Andrew K Lee; Christopher J Logothetis; Jeri Kim
Journal:  BJU Int       Date:  2015-04-21       Impact factor: 5.588

6.  Prostate cancer detection by prostate-specific antigen-based screening in the Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection.

Authors:  Jun Teishima; Satoshi Maruyama; Hideki Mochizuki; Kiyotaka Oka; Kenichiro Ikeda; Keisuke Goto; Hirotaka Nagamatsu; Keisuke Hieda; Koichi Shoji; Akio Matsubara
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

7.  Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison.

Authors:  Alice Dragomir; Fabio L Cury; Armen G Aprikian
Journal:  CMAJ Open       Date:  2014-04-24

8.  Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study.

Authors:  Frances Josephine Drummond; Heather Kinnear; Eamonn O'Leary; Anna Gavin; Linda Sharp
Journal:  J Cancer Surviv       Date:  2015-01-07       Impact factor: 4.442

9.  Gleason score and tumor laterality in radical prostatectomy and transrectal ultrasound-guided biopsy of the prostate: a comparative study.

Authors:  Renan A Pereira; Roberto S Costa; Valdair F Muglia; Fábio Franca Silva; Joyce S Lajes; Rodolfo B Dos Reis; Gyl Eb Silva
Journal:  Asian J Androl       Date:  2015 Sep-Oct       Impact factor: 3.285

Review 10.  Health-related quality of life among long-term (≥5 years) prostate cancer survivors by primary intervention: a systematic review.

Authors:  Salome Adam; Anita Feller; Sabine Rohrmann; Volker Arndt
Journal:  Health Qual Life Outcomes       Date:  2018-01-23       Impact factor: 3.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.